Latest Research And Development News

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Delorean Corporation has banked a $5.76 million cash refund from the Australian Government’s FY2025 R&D Tax Incentive, underpinning its bioenergy infrastructure growth. Another refund linked to FY2026 expenditure is anticipated next year.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Unith Ltd (ASX:UNT) posted Q3 FY2026 revenue of A$1.26 million, secured a $2 million finance facility to fuel commercial expansion, and showcased significant advancements in its AI Digital Humans platform, including proprietary streaming technology and SDK launches.

BPH Global’s Indonesian unit has locked in a four-year MoU with ITBM to integrate student-driven operations and research at its Takalar coastal seaweed site, setting the stage for scaled commercial development and local collaboration.

Andromeda Metals has secured a $1.66 million cash refund from the Australian Government's R&D Tax Incentive program, reflecting $3.4 million of eligible expenditure tied to its Great White Project.

Arovella Therapeutics undergoes a major board overhaul and CEO resignation following a shareholder push, as the company embarks on a strategic review of its cell therapy platform.

Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.

Brazilian Critical Minerals (ASX: BCM) has locked in pre-approval under Australia’s R&D Tax Incentive for its Ema Rare Earth Project, including critical overseas activities in Brazil. This reduces regulatory uncertainty and supports funding efficiency for advancing the project’s development.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

ReNerve Limited reports a 79% jump in quarterly sales, secures key Asia-Pacific approvals, and progresses its nerve repair pipeline with the NervAlign Nerve Guide Matrix entering Stage 3 development.

Marquee Resources has significantly increased its Mt Clement inferred antimony resource and is advancing drilling and strategic partnerships to develop its flagship project.